Core Viewpoint - The article discusses the recent A+ round financing of Zhiran Medical, a company specializing in invasive flexible electrode brain-machine interfaces, which raised 300 million RMB to advance clinical trials and product iterations [4][6]. Financing Overview - Zhiran Medical completed its A+ round financing on February 11, 2026, raising 300 million RMB, led by Zhongke Chuangxing, with participation from various investors including Legend Capital and IDG Capital [4][5]. - The company has a history of financing rounds, including over 300 million RMB in its A round in July 2025 and undisclosed amounts in earlier rounds [5]. Technological Advancements - The company has developed a new type of stretchable flexible electrode that addresses the core issues of traditional electrodes, such as displacement and detachment in the brain, allowing for precise and stable neural signal collection [4][15]. - This innovative technology significantly reduces mechanical damage to brain tissue, with the required stretching force being only 1/100 of that needed for traditional linear electrodes [15][12]. Product and Market Strategy - Zhiran Medical's core product is an invasive flexible brain-machine interface platform, which includes flexible electrodes, hardware systems, software, and decoding algorithms [11]. - The company aims to meet clinical needs by developing products that assist patients with paralysis, blindness, and neurological disorders [6][9]. Clinical Applications and Collaborations - The company has initiated collaborations with hospitals for clinical implantation surgeries, including a successful ultra-thin flexible deep electrode implantation in November 2024 [24]. - Zhiran Medical's digital EEG machine, capable of 1024-channel signal collection, received market approval in May 2025, catering to diverse clinical and research needs [20][21]. Production Capabilities - The company has established its own production facility for clinical-grade flexible electrodes, with a cleanroom area of nearly 2000 square meters, achieving mass production capabilities [24]. - The electrode implantation robot developed by Zhiran Medical enhances precision and efficiency in surgical procedures, reducing the time for single electrode implantation to under 30 seconds [18][19]. Future Outlook - Zhiran Medical plans to accelerate the clinical rollout of its products, with large-scale registration of over 100-channel invasive brain-machine interface products expected to start in 2026 [26]. - The long-term vision of the company is to bridge the gap between humans and machines, ultimately enhancing human brain functions [26].

Core Viewpoint - The brain-computer interface (BCI) sector is gaining momentum, with significant developments from companies like Neuralink and BoRuiKang, indicating a potential boom in the market by 2026 [1][7]. Company Developments - Neuralink, founded by Elon Musk, aims for large-scale production of its devices by 2026, which has positively impacted global stock markets [1]. - BoRuiKang, a Chinese BCI company, is preparing for an IPO on the Sci-Tech Innovation Board after completing its counseling registration with the Shanghai Securities Regulatory Bureau [2]. - BoRuiKang's founder, Xu Honglai, has a strong academic background in biomedical engineering from Tsinghua University and has been pivotal in the company's development since its establishment in 2011 [3][4]. Product Innovations - BoRuiKang's notable product, the NEO system, utilizes a "semi-invasive" technique for brain interface implantation, which minimizes damage to neural tissue and avoids the need for batteries in the brain [4]. - The company has achieved significant milestones, including the first human implantation surgery in Shanghai in November 2024, with patients showing rapid recovery [4][5]. Market Trends - The global BCI market is projected to grow from $2.62 billion in 2024 to over $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35%, driven by the demand for treatments of neurological diseases and rehabilitation [8]. - In China, the BCI market is expected to reach 3.2 billion yuan in 2024, with projections of 6.14 billion yuan by 2028, indicating a doubling in four years [10]. Investment Landscape - BoRuiKang has attracted significant investment, with its valuation estimated between 3.5 billion to 4 billion yuan following its D-round financing [5]. - The company has received backing from prominent investors such as Sequoia China and Baidu Ventures, highlighting the growing interest in the BCI sector [4]. Competitive Landscape - The BCI industry is characterized by a mix of domestic and international players, with varying technological approaches. BoRuiKang focuses on both non-invasive and semi-invasive solutions, while competitors like Neuralink are exploring multi-channel flexible electrodes [12]. - The domestic market is witnessing a shift towards local production, with a current market share of 15-20% for domestic core devices, as companies like BoRuiKang lead in the non-invasive EEG collection segment [10][11].

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]

Group 1: Neuralink's Developments - Neuralink has showcased its latest research achievements and future plans through a one-hour video, highlighting the capabilities of its N1 chip for controlling devices with thoughts [2] - The N1 chip, the size of a coin, features 1024 electrodes that capture brain signals in real-time and convert them into digital commands, with seven subjects currently implanted [2][3] - Future plans include increasing electrode counts to 3,000 by 2026, 10,000 by 2027, and over 25,000 by 2028, aiming to treat mental disorders and enhance human-machine interaction [3] Group 2: Market Potential and Growth - The brain-computer interface (BCI) industry is recognized as a groundbreaking field with significant potential across medical, technological, and entertainment sectors [4][6] - The global BCI market size has grown from $1.2 billion in 2019 to $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [6] - By 2029, the global BCI industry is projected to reach $7.63 billion, indicating strong growth despite current clinical trial limitations and ethical challenges [7] Group 3: China's BCI Industry - China has over a hundred companies with products in clinical stages, with leading firms including Pinchi Medical and Zhejiang Yiyang focusing on various BCI applications [9][10] - The aging population and high prevalence of neurological diseases in China create a robust market demand for BCI technologies, with expectations for the industry to exceed 10 billion yuan by 2029 [10]

Core Insights - The brain-computer interface (BCI) sector is experiencing significant advancements, with various developments in policy, clinical applications, and technology integration [1][4][6] Policy Developments - Sichuan province has launched a comprehensive action plan for brain-computer interface and human-computer interaction industries from 2025 to 2030, aiming to develop multiple BCI products and enhance clinical applications [4][5] - National policies are being introduced to support the development of BCI technology, including quality requirements for medical devices using BCI technology and guidelines for pricing new neuro-related medical services [4][5] Market Potential - The global BCI market is projected to reach $3.3 billion by 2027, with a compound annual growth rate (CAGR) of approximately 13.5% since 2019 [2] - In China, the BCI market is expected to grow to 3.2 billion yuan in 2024, with an annual growth rate of 18.8%, and is forecasted to exceed 5.5 billion yuan by 2027 [3] Clinical Applications - BCI technology is being applied in various medical fields, particularly in treating cognitive and motor disorders, with significant clinical trials underway [6][8] - The first clinical ward for BCI technology has been established at Beijing Tiantan Hospital, focusing on research and clinical trials [6] Technological Integration - Synchron has partnered with Apple to integrate its BCI device with Apple products, allowing users to control devices using only their thoughts [7] - Neuralink's BCI device has received "breakthrough medical device" designation from the FDA, targeting patients with severe neurological conditions [7][8] Future Outlook - The BCI industry is expected to continue evolving, with increasing clinical applications and technological advancements, although challenges related to safety, ethics, and privacy remain [8]